Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

This study is currently recruiting participants.
Verified June 2013 by Regimmune Inc.
Sponsor:
Collaborator:
Pacific-Link Regulatory Consulting LLC
Information provided by (Responsible Party):
Regimmune Inc.
ClinicalTrials.gov Identifier:
NCT01379209
First received: June 17, 2011
Last updated: June 27, 2013
Last verified: June 2013
  Purpose

The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.

The study will be separated into two parts; a dose escalation phase to assess safety, followed by a large expansion phase to further evaluate the pharmacologic effects of either a Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include higher risk patients and limit the unrelated donor transplants. After safety is established in part 1 of the study, the second portion of the study will expand the enrollment criteria and allow transplantation by either related or unrelated donors.

This study will endeavor to identify the dose range at which RGI-2001 has an acceptable safety profile, at which biologic activity is observed, and to guide possible dose levels to utilize in later phase studies based on biological activity.


Condition Intervention Phase
Prevention of GvHD in Patients With Hematological Malignancies Undergoing AHSCT
Drug: RGI-2001
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Resource links provided by NLM:


Further study details as provided by Regimmune Inc.:

Primary Outcome Measures:
  • The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001 [ Time Frame: By day 29 ] [ Designated as safety issue: Yes ]

    The primary outcome measures are:

    • The incidence and severity of adverse events
    • The maximum tolerated dose (MTD) or maximum feasible dose (MFD) of RGI-2001, administered as a single intravenous infusion approximately 30 minutes after AHSCT


Secondary Outcome Measures:
  • Pharmacodynamic Effects [ Time Frame: Within 100 days from AHSCT ] [ Designated as safety issue: Yes ]
    Evaluate biomarkers to assess the potential pharmacodynamic effects of RGI-2001 through biomarkers and cytokine assessments. Exploratory biomarkers for efficacy in reducing GvHD include IL-2R, TNFR1, HGF. Cytokines will be evaluated for both safety and for evidence of mechanism of action and include IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, MIG, TNF-α and IFN-γ.

  • Pharmacokinetics of RGI-2001 [ Time Frame: Within first 8 days ] [ Designated as safety issue: No ]
    Obtain pharmacokinetic parameters such as Cmax, Cmin, Tmax, AUC and half-life of the study drug in plasma.

  • Efficacy in reducing the intensity of GvHD [ Time Frame: Within the first 100 days after AHSCT ] [ Designated as safety issue: No ]
    The time to onset, peak intensity and course of GvHD after the AHSCT procedure will be monitored according to the Modified Keystone Criteria for Acute Graft-Versus-Host Disease.

  • Optimal Dose of RGI-2001 [ Time Frame: Within first 100 days after AHSCT ] [ Designated as safety issue: No ]
    Determine optimal doses of RGI-2001 for further evaluation based on pharmacodynamic response and effectiveness in reducing the intensity of GvHD


Estimated Enrollment: 71
Study Start Date: September 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RGI-2001
Dose escalation group in part 1 of this study will include 3 to 6 patients each group and up to 7 dose groups. In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons.
Drug: RGI-2001
RGI-2001 is a liposomal formulation of the α-galactosylceramide class of compound [(2S,3S,4R)-1-o-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol]. RGI-2001 is provided as an intravenous administration after AHSCT is complete. A single administration of RGI-2001 will be used in this trial. The study will last for 101 days in total; 29 days for safety and 101 days for evaluation of GvHD.
Other Names:
  • KRN-7000
  • RGI-7000

Detailed Description:

The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.

In Part 1 (Phase 1: Dose Escalation Phase), patients will receive a single intravenous administration of RGI-2001 approximately 30 minutes after completion of the transplant (either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified)) with the dosage based upon the assigned treatment cohort. Eligible patients will be enrolled in five to seven centers in the United States. Patients who are undergoing AHSCT will be enrolled in a sequential group dose-escalating fashion to determine the safety, tolerability, pharmacokinetic profile, and the MTD or MFD of RGI-2001. It is anticipated that up to six dose levels will be evaluated in Part 1, with an option for an additional cohort (Cohort 7) if the MTD is not reached and pharmacodynamic markers suggest higher doses are warranted.

In Part 2 (Expansion Phase), one or more doses below the MTD or MFD will be selected based on a potential correlation between GvHD and biological activity to further assess safety and biologic activity. Approximately 30 patients who are undergoing either allogeneic PBSCs or allogenic bone marrow transplantation (unmodified) will be enrolled in Part 2 of the study.

Patients will be monitored for safety for 29 days after the transplant procedure.

All patients will be followed for 100 days following transplant procedure for the incidence of acute GvHD, according to the Modified Keystone Criteria for grading acute GvHD (Przepiorka D, et al)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has a hematological malignancy or aplastic anemia (AA) and is undergoing a first allogeneic transplant procedure.
  2. Meet one of the following underlying disease criteria:

    a. Acute myelogenous leukemia (AML) i. First or subsequent morphologic remission b. Acute lymphoblastic leukemia (ALL) i. First or subsequent morphologic remission c. Chronic myelogenous leukemia (CML) i. Chronic phase; or ii. Accelerated phase d. Multiple Myeloma (MM) i. Not more than 20% plasma cells in the bone marrow e. Myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia (CMML), who have received at least one previous induction regimen and have <10% blasts f. Myeloproliferative disorder (MPD), including; i. myeloid metaplasia, and ii. myelofibrosis g. Non-Hodgkin's Lymphoma (NHL) i. High-risk NHL in first remission; or ii. Relapsed or refractory NHL h. Hodgkin's lymphoma (HL) beyond first remission i. Aplastic anemia (AA)

  3. Male or female, age ≥18 years of age
  4. Reasonable expectation of survival for at least 3 months, if the transplant procedure is successful
  5. Eastern Cooperative Oncology Group (ECOG) status of 0-2 or Karnofsky Performance Status (KPS) of > 60
  6. Transplant Donor

    1. Part 1 (Phase 1: Dose Escalation Phase):

      Unrelated transplant donor with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded)

    2. Part 2 (Phase 2a: Expansion Phase):Related or unrelated transplant donor, with no more than 1 HLA allele or antigen mismatch, defined as loci A, B, C and DR (note: DQ is excluded).
  7. Source of the allograft

    1. Part 1 (Phase 1: Dose Escalation Phase):Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
    2. Part 2: (Phase 2a: Expansion Phase) Unmodified (non-manipulated) bone marrow, or mobilized peripheral blood stem cell (PBSC) transplant, using G-CSF as the mobilizing agent.
  8. Anti-graft-versus-host disease (GvHD) prophylaxis:

    A calcineurin inhibitor [either tacrolimus (FK506) or cyclosporin A)], in combination with either methotrexate (MTX), mycophenolate mofetil (MMF) or sirolimus (RAPA) all at doses as per the institutional protocols

  9. Adequate hepatic function, with bilirubin not exceeding the upper limit of normal (except when attributed to Gilbert's Disease), and AST and ALT of less than 1.5 times the upper limit of normal
  10. No clinically significant cardiac conduction disorder on screening ECG
  11. Serum creatinine ≤ 2.0 mg/dL
  12. Female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment and must agree to use dual method of contraception for 30 days after study drug administration. Approved methods of contraception include, an IUD with spermicide, a female condom with spermicide, a diaphragm with spermicide, a cervical cap with spermicide, use of a condom with spermicide by sexual partner or a sterile sexual partner.
  13. If male, subjects must be sterile or willing to use an approved method of contraception from the time of Informed Consent to 30 days after study drug treatment. Males must be willing to refrain from sperm donation within 30 days after study drug treatment.
  14. No clinically significant acute or chronic medical condition that in the opinion of the investigator will interfere with study participation
  15. No clinically significant laboratory abnormalities as determined by the Principal Investigator, in consultation with the Sponsor's Medical Monitor
  16. No active infection
  17. Have signed written informed consent before undergoing any study related procedures and is willing to comply with all study procedures

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating
  2. Subjects about to undergo a non-ablative or non-myeloablative transplant
  3. AML or ALL patient who are in relapse (>5% blasts) or who are defined as primary refractory
  4. Blast crisis CML
  5. Radiation, chemotherapy, immunotherapy in the previous 3 weeks, unrelated to the transplant procedure
  6. Subjects who, in the judgment of the Investigator have not recovered from the effects of previous therapy
  7. Subject who is about to undergo cord blood transplantation
  8. Procedures that are intended to deplete regulatory T-cells from donor transplant materials
  9. Known or suspected HIV infection
  10. Active hepatitis A, B, or C infection in recipient or donor
  11. Uncontrolled active infection requiring IV antibiotics in recipient or donor
  12. Major surgery within 1 month before Day 0
  13. Participation in an investigational study within 1 month prior to Day 0
  14. Prior treatment with anti-CD3 antibodies
  15. Treatment with anti-CD20 antibodies or anti-thymocyte globulin (ATG) within 3 months of the AHSCT procedure (i.e. infusion of transplant material and RGI-2001).
  16. Vaccination within the preceding 2 weeks prior to the planned dose of RGI-2001
  17. Planned vaccination within 2 months after study drug administration
  18. Known history of cardiac dysfunction (e.g. <50% ejection fraction), ischemia, conduction abnormalities, or myocardial infarction in the previous six months
  19. Cardiac pacemaker or automatic implantable cardioverter-defibrillator
  20. Marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms
  21. Congenital long QT syndrome or family history of long QT syndrome
  22. History of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia)
  23. Bundle branch block
  24. Connective tissue/rheumatologic disorders
  25. History of autoimmune disease
  26. History of solid tumor, excluding non-melanoma skin or cervical carcinoma after curative resection, within the preceding 5 years
  27. Uncontrolled diabetes
  28. Prior allogeneic hematopoietic stem cell transplantation
  29. Any other prior organ transplant
  30. Psychiatric or addictive disorders that preclude obtaining reliable informed consent
  31. Any other condition that, in the opinion of the investigator, renders the subject unsuitable for study participation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01379209

Locations
United States, California
UCSD Moores Cancer Research Institute Recruiting
San Diego, California, United States, 93093
Contact: Edward Ball, MD    858-822-6842    tball@ucsd.edu   
Principal Investigator: Edward (Ted) Ball, MD         
Stanford School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Laura Johnston, MD    650-723-0822    korb@stanford.edu   
Principal Investigator: Laura Johnston, MD         
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Alandra Powe    813-745-6040    alandra.powe@moffitt.org   
Contact: Michelle Burton, RN    813-745-2556    Michelle.Burton@moffitt.org   
Principal Investigator: Joseph Pidala, MD         
United States, Ohio
Ohio State University Comprehensive Cancer Center - The James Recruiting
Columbus, Ohio, United States, 43210
Contact: Yvonne A Efebera, MD    614-293-2268    yvonne.efebera@osumc.edu   
Contact: Steven Devine, MD    614-293-5655    devine.54@osu.edu   
Principal Investigator: Yvonne A. Efebera, MD         
Sub-Investigator: Steven Devine, MD         
United States, Texas
Methodist Healthcare System Recruiting
San Antonio, Texas, United States, 78229
Contact: Sherri Shade, RN    210-575-4238    Sherri.Shade@MHShealth.com   
Contact: Jo Dell McCracken, RN    (210) 575-4281    Jodell.Mccracken@MHShealth.com   
Principal Investigator: Carlos R Bachier, MD         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Contact: Paul Martin, MD    206-667-5000    pmartin@fhcrc.org   
Contact: Terry Furlong    206-667-5000    tfurlong@fhcrc.org   
Principal Investigator: Paul Martin, MD         
Sponsors and Collaborators
Regimmune Inc.
Pacific-Link Regulatory Consulting LLC
  More Information

Additional Information:
No publications provided

Responsible Party: Regimmune Inc.
ClinicalTrials.gov Identifier: NCT01379209     History of Changes
Other Study ID Numbers: RGI-2001-02
Study First Received: June 17, 2011
Last Updated: June 27, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Regimmune Inc.:
AHSCT
Bone Marrow Transplant
Leukemia
myelodysplastic syndrome
hematological malignancies
Graft-versus-host-disease
GvHD
Hematopoietic Stem Cell Transplantation
Stem Cell
Transplantation

Additional relevant MeSH terms:
Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases

ClinicalTrials.gov processed this record on April 23, 2014